Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results